3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
109
Cyclophosphamide
87
fludarabine
68
Carboplatin
57
Injections
56
Bevacizumab
50
Specimen Handling
43
Gemcitabine
41
Magnetic Resonance Spectroscopy
40
Paclitaxel
39
Nivolumab
38
venetoclax
36
Dexamethasone
35
Cisplatin
35
Biopsy
34
Temozolomide
31
Docetaxel
29
Capecitabine
27
atezolizumab
26
Oxaliplatin
26
Fluorouracil
26
Pemetrexed
24
Irinotecan
24
Azacitidine
24
abemaciclib
23
toripalimab
22
Fulvestrant
22
Rituximab
21
fludarabine phosphate
20
durvalumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recruiting
×
Histamine Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled